These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37791528)

  • 21. Covalent Docking in Drug Discovery: Scope and Limitations.
    Scarpino A; Ferenczy GG; Keserű GM
    Curr Pharm Des; 2020; 26(44):5684-5699. PubMed ID: 33155894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Covalent fragment libraries in drug discovery.
    Keeley A; Petri L; Ábrányi-Balogh P; Keserű GM
    Drug Discov Today; 2020 Jun; 25(6):983-996. PubMed ID: 32298798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRAS
    Li KS; Quinn JG; Saabye MJ; Guerrero JFS; Nonomiya J; Lian Q; Phung W; Izrayelit Y; Walters BT; Gustafson A; Endres NF; Beresini MH; Mulvihill MM
    Anal Chem; 2022 Jan; 94(2):1230-1239. PubMed ID: 34990117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond cysteine: recent developments in the area of targeted covalent inhibition.
    Mukherjee H; Grimster NP
    Curr Opin Chem Biol; 2018 Jun; 44():30-38. PubMed ID: 29857316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Covalent drug discovery exploiting the new warheads].
    Ojida A
    Nihon Yakurigaku Zasshi; 2022; 157(5):361-365. PubMed ID: 36047154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Covalent inhibitors: back on track?
    Gehringer M
    Future Med Chem; 2020 Aug; 12(15):1363-1368. PubMed ID: 32597212
    [No Abstract]   [Full Text] [Related]  

  • 29. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
    Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in covalent drug discovery.
    Boike L; Henning NJ; Nomura DK
    Nat Rev Drug Discov; 2022 Dec; 21(12):881-898. PubMed ID: 36008483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covalent peptides and proteins for therapeutics.
    Berdan VY; Klauser PC; Wang L
    Bioorg Med Chem; 2021 Jan; 29():115896. PubMed ID: 33285408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysine-Targeted Inhibitors and Chemoproteomic Probes.
    Cuesta A; Taunton J
    Annu Rev Biochem; 2019 Jun; 88():365-381. PubMed ID: 30633551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactive-cysteine profiling for drug discovery.
    Maurais AJ; Weerapana E
    Curr Opin Chem Biol; 2019 Jun; 50():29-36. PubMed ID: 30897495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.
    McLean LR; Zhang Y; Li H; Li Z; Lukasczyk U; Choi YM; Han Z; Prisco J; Fordham J; Tsay JT; Reiling S; Vaz RJ; Li Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6717-20. PubMed ID: 19836948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors.
    Kemp M
    Prog Med Chem; 2016; 55():149-92. PubMed ID: 26852935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.